ZVRA Stock Forecast & Price Target

Zevra Therapeutics is supported by a durable U.S. MIPLYFFA launch, with 2Q26 net sales of $30.2 million, 184 cumulative enrollment forms, and stable payer coverage at 69% of covered lives, while its integrated patient-finding strategy appears capable of expanding beyond the initially diagnosed 300–350 U.S. NPC patients toward an estimated ~900-patient pool. The company’s balance sheet further strengthens the thesis, with $260.2 million in cash, cash equivalents and investments, no debt, and enough liquidity to fund MIPLYFFA, pursue a potential European re-examination outcome expected in 4Q26, and advance celiprolol. MIPLYFFA’s 2041 patent protection, high patient persistence, and possible European approval create long-duration revenue optionality, while celiprolol could become a meaningful second franchise by leveraging the existing rare-disease commercial infrastructure.

Zevra Therapeutics is exposed to substantial fundamental risk because its commercial success for Miplyffa still depends on expanding access while facing potential EMA approval failure, safety or tolerability issues, and competitive pressure from a recent rival approval that could slow the sales ramp and limit peak penetration. Even with a U.S. marketed product, the company remains vulnerable to weaker payer uptake, lower full access if payers favor the competitor, and the possibility that pipeline candidates fail in the clinic or are held back by FDA or other regulatory demands for additional studies. Its financial profile is also fragile, with a history of losses, no established profitability track record, and likely need for additional capital to support commercialization, while litigation and partnership execution risks could further impair value creation.